瑞他鲁肽 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-15. Anything still debated is marked as such rather than presented as settled.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
== Medical use == Ethacrynic acid is a diuretic that is used to treat edema when a stronger agent is required. It is available as a pill or injected form. The pill is used to treat edema associated with congestive heart failure, cirrhosis and renal disease, accumulation of liquid in the belly associated with cancer or edema, and management of hospitalized children with congenital heart disease or nephrotic syndrome. The injected form is used to rapidly remove water from the body when needed – for example in acute pulmonary edema – or when a person cannot take the medicine in pill form.
== Fuels and consumption == Ashing is a test to deduce the amount of ash forming material present in a petroleum product so as to decide its use in certain applications. Ash-forming materials are considered to be undesirable impurities or contaminants. In the ash analysis of petroleum products, ash content represents the incombustible component remaining after a sample of the furnace oil is completely burned. The ash content of petroleum products is generally low. It is defined as the inorganic residue that remains after combustion of the oil in air at specific high temperature. Ash typically ranges from 0.1 to 0.2% in oil. Some of the ash forming constituents occur naturally in crude oil; others are present as a result of refining or contamination during storage or distribution. Knowledge of the amount of ash-forming material present in a product can provide information as to whether or not the product is suitable application. In the ash analysis of coal and other solid fuels, the amount of sulfur retained in the ash during the ashing process is not constant, but rather is dependent upon the conditions of ashing as well as the other inorganic constituents in the ash that may form sulfates during the ashing procedure. As such, different ashing procedures may yield different ash contents.
== Notable people == Túpac Amaru II, revolutionary Angélica Mendoza de Ascarza, Peruvian human rights activist Kimberly Barzola, American community organizer and artist Benjamin Bratt, American actor Manco Cápac, Sapa Inca Luzmila Carpio, Bolivian musician Andrónico Rodríguez, Bolivian trade unionist and politician Martín Chambi, Peruvian photographer Renata Flores Rivera, Peruvian musician Oswaldo Guayasamín, Ecuadorian painter Ollanta Humala, former president of Peru Antauro Humala, Peruvian ethnocacerist Josh Keaton, American actor Q'orianka Kilcher, American actress Nancy Iza Moreno, Kichwa leader Leonidas Iza, Ecuadorian activist and Indigenous leader Delfín Quishpe, Ecuadorian musician and politician Tarcila Rivera Zea, Peruvian activist Izkia Siches, Chilean physician and politician Magaly Solier, Peruvian actress and musician Diego Quispe Tito, painter Francisco Tito Yupanqui, sculptor Alejandro Toledo, former president of Peru Edison Flores, Peruvian footballer Renato Tapia, Peruvian footballer Tania Pariona Tarqui, Peruvian politician
A study in which the participants are assigned by chance to separate groups that compare different treatments; neither the researchers nor the participants can choose which group. Using chance to assign people to groups means that the groups will be similar and that the treatments they receive can be compared objectively. At the time of the trial, it is not known which treatment is best. It is the patient's choice to be in a randomized trial. (NCI) A study in which participants are randomly (i.e., by chance) assigned to one of two or more treatment arms of a clinical trial. Occasionally placebos are utilized. (NLM) Recruiting
Initially, Owens believed the Wests had been sincere in their apologies and obliged, believing she had simply mistaken their earlier intentions. Rose joined her in the back seat, with the explanation she wanted a "girls' chat" as Fred drove. Shortly thereafter, Rose began to fondle Owens, as Fred questioned whether she had had sex with her boyfriend that evening. When Owens began to protest, Fred stopped the car, referred to Owens as a "bitch" and punched her into unconsciousness before he and Rose bound and gagged her with a scarf and duct tape. In her subsequent statement to police, Owens stated that, at Cromwell Street, she was given a drugged cup of tea to drink before being again gagged and subjected to a prolonged sexual assault from the Wests. When Owens screamed, Rose smothered her with a pillow, further restrained her about the neck and performed cunnilingus on her. Realising the gravity of her situation, Owens ceased resisting their sexual assaults. The following morning, having noted Owens' screaming when one of his children had knocked on the door of the room in which she was restrained, Fred threatened that he and his wife would keep her locked in the cellar and allow his "black friends" to abuse her, and that when they had finished he would bury her body beneath "the paving stones of Gloucester." Fred then claimed he had killed hundreds of young girls, adding that Owens had primarily been brought to the house for "Rose's pleasure." He and Rose then calmly asked Owens whether she would consider returning to work as their nanny.
Sources: en.wikipedia.org
== Weaknesses == The assay is limited to using existing restriction sites in the region of interest, and methylation that does not occur in the context of a specific restriction site will not be assayed. Incomplete digestion by restriction enzymes after PCR can confound the analysis: incomplete digestion would suggest lack of DNA methylation (if cutting with a methylation-sensitive enzyme such as HpaII). It is also known that BstUI can cut at unconverted sites, leading to overestimation of methylation levels and so the use of HpaII is often needed. In complex samples, cell-type heterogeneity can confound the analysis since the DNA is not being sequenced, heterogeneity in sequences from different cells in the sample (i.e. different cell populations within a tumor) that have acquired mutations in the interrogated region, such as changing the CG dinucleotide to CA or CT, would result in loss of the restriction site giving rise to an apparently methylated region due to lack of digestion. This would skew the quantification of DNA methylation levels in a given sample.
anaphase lag The failure of one or more pairs of sister chromatids or homologous chromosomes to properly migrate to opposite sides of the cell during anaphase of mitosis or meiosis due to a defective spindle apparatus. Consequently, both daughter cells are aneuploid: one is missing one or more chromosomes (creating a monosomy) while the other has one or more extra copies of the same chromosomes (creating a polysomy).
=== Amino acid synthesis === Six essential amino acids and three nonessential are synthesized from oxaloacetate and pyruvate. Aspartate and alanine are formed from oxaloacetate and pyruvate, respectively, by transamination from glutamate. Asparagine is synthesized by amidation of aspartate, with glutamine donating the NH4. These are nonessential amino acids, and their simple biosynthetic pathways occur in all organisms. Methionine, threonine, lysine, isoleucine, valine, and leucine are essential amino acids in humans and most vertebrates, meaning that oxaloacetate cannot be converted into any of these aminos. However they can be synthesizers in bacteria via biosynthetic pathways that are complex and interconnected.
== Company structure == Metrohm is a stock corporation headquartered in Herisau, Switzerland. It is owned by the Metrohm Foundation, which ensures the company's independence. Metrohm is present in around 80 countries through subsidiaries or distribution partners. Amongst others, Metrohm holds the following specialized development and production sites:
Sources: en.wikipedia.org
== Diagnosis == Buried bumper syndrome may be suspected based on features consistent with this disorder. The diagnosis is confirmed either endoscopically (via upper endoscopy) or with computed tomography. Upper endoscopy may reveal overgrowth of stomach tissue over the internal bumper (incomplete buried bumper syndrome). If the bumper has eroded deep into the gastric mucosa, it may not be visualized during endoscopic evaluation (complete buried bumper syndrome).
==== 2020 kimchi ISO standard dispute with China ==== In November 2020, the International Organization for Standardization (ISO) posted ISO 24220:2020, new regulations for the making of pao cai. The same month, BBC News reported that Chinese news organization Global Times claimed the new ISO standard was "an international standard for the kimchi industry led by China" despite the standard clearly stating "this document does not apply to kimchi". This sparked strong anger from South Korean media and people, as well as the responses from some Chinese people who argued China held the right to claim kimchi as their own. However clarifications from both countries, later revealed that the controversy was triggered over a misunderstanding of a translation of the Chinese word pao cai. After the controversy emerged, Global Times explained it was simply a "misunderstanding in translation", where they had meant to refer to Chinese pao cai, and their Chinese language article had used the term pao cai, but their English language version had "erroneously" translated it as "kimchi", and that the dispute arose from being innocently "lost in translation".
Such methods have been applied for discovering protein interactions on human interactome, specifically the interactome of Membrane proteins and the interactome of Schizophrenia-associated proteins. As of 2020, a model using residue cluster classes (RCCs), constructed from the 3DID and Negatome databases, resulted in 96-99% correctly classified instances of protein–protein interactions. RCCs are a computational vector space that mimics protein fold space and includes all simultaneously contacted residue sets, which can be used to analyze protein structure-function relation and evolution.
== Research == A 2016 review found that reserpine reduced systolic blood pressure (SBP) by about 8 mmHg compared to placebo, and may be as effective at reducing SBP as other front-line hypertensive drugs, although more research is needed to determine a dose-specific safety profile.
Agrobacterium tumefaciens is the causal agent of crown gall disease (the formation of tumours) in over 140 species of eudicots. It is a rod-shaped, Gram-negative soil bacterium. Symptoms are caused by the insertion of a small segment of DNA (known as T-DNA, for 'transfer DNA', not to be confused with tRNA that transfers amino acids during protein synthesis), from a plasmid into the plant cell, which is incorporated at a semi-random location into the plant genome. Plant genomes can be engineered by use of Agrobacterium for the delivery of sequences hosted in T-DNA binary vectors. Agrobacterium tumefaciens is an Alphaproteobacterium of the family Rhizobiaceae, which includes the nitrogen-fixing legume symbionts. Unlike the nitrogen-fixing symbionts, tumor-producing Agrobacterium species are pathogenic and do not benefit the plant. The wide variety of plants affected by Agrobacterium makes it of great concern to the agriculture industry. Economically, A. tumefaciens is a serious pathogen of walnuts, grape vines, stone fruits, nut trees, sugar beets, horseradish, and rhubarb, and the persistent nature of the tumors or galls caused by the disease make it particularly harmful for perennial crops. Agrobacterium tumefaciens grows optimally at 28 °C (82 °F). The doubling time can range from 2.5–4h depending on the media, culture format, and level of aeration. At temperatures above 30 °C (86 °F), A. tumefaciens begins to experience heat shock which is likely to result in errors in cell division.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。